Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, suggests that combining ruxolitinib, a commonly used JAK inhibitor, with drugs that target other pathways involved in disease progression is an effective way to manage difficult-to-treat patients with myelofibrosis (MF). Two promising combinations include pelabresib and navitoclax, which have shown clinical responses and improvements in bone marrow fibrosis and JAK2 allele burden in early-phase trials. Large Phase III randomized trials are currently testing the efficacy of these combinations as first-line therapy. Additionally, a drug called navtemadlin is also being evaluated in a Phase III trial in patients with MF. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.